Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome
Radiolabeled annexin V may provide an early indication of the success or failure of anticancer therapy on a patient-by-patient basis as an in vivo marker of tumor cell killing. An important question that remains is when, after initiation of treatment, should annexin V imaging be performed. To addres...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2004-01-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1162/15353500200403157 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841563186939035648 |
|---|---|
| author | Stefanie J. Mandl Carina Mari Matthias Edinger Robert S. Negrin Jonathan F. Tait Christopher H. Contag Francis G. Blankenberg |
| author_facet | Stefanie J. Mandl Carina Mari Matthias Edinger Robert S. Negrin Jonathan F. Tait Christopher H. Contag Francis G. Blankenberg |
| author_sort | Stefanie J. Mandl |
| collection | DOAJ |
| description | Radiolabeled annexin V may provide an early indication of the success or failure of anticancer therapy on a patient-by-patient basis as an in vivo marker of tumor cell killing. An important question that remains is when, after initiation of treatment, should annexin V imaging be performed. To address this issue, we obtained simultaneous in vivo measurements of tumor burden and uptake of radiolabeled annexin V in the syngeneic orthotopic murine BCL 1 lymphoma model using in vivo bioluminescence imaging (BLI) and small animal single-photon emission computed tomography (SPECT). BCL 1 cells labeled for fluorescence and bioluminescence assays (BCL 1 − gfp/luc ) were injected into mice at a dose that leads to progressive disease within two to three weeks. Tumor response was followed by BLI and SPECT before and after treatment with a single dose of 10 mg/kg doxorubicin. Biodistribution analyses revealed a biphasic increase of annexin V uptake within the tumor-bearing tissues of mice. An early peak occurring before actual tumor cells loss was observed between 1 and 5 hr after treatment, and a second longer sustained rise from 9 to 24 hr after therapy, which heralds the onset of tumor cell loss as confirmed by BLI. Multimodality imaging revealed the temporal patterns of tumor cell loss and annexin V uptake revealing a better understanding of the timing of radiolabeled annexin V uptake for its development as a marker of therapeutic efficacy. |
| format | Article |
| id | doaj-art-fabfffc2f3e2460a8c3153b68dbd3cdd |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2004-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-fabfffc2f3e2460a8c3153b68dbd3cdd2025-01-03T00:11:24ZengSAGE PublishingMolecular Imaging1536-01212004-01-01310.1162/1535350020040315710.1162_15353500200403157Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic OutcomeStefanie J. Mandl0Carina Mari1Matthias Edinger2Robert S. Negrin3Jonathan F. Tait4Christopher H. Contag5Francis G. Blankenberg6Stanford UniversityStanford UniversityStanford UniversityStanford UniversityUniversity of WashingtonStanford UniversityStanford UniversityRadiolabeled annexin V may provide an early indication of the success or failure of anticancer therapy on a patient-by-patient basis as an in vivo marker of tumor cell killing. An important question that remains is when, after initiation of treatment, should annexin V imaging be performed. To address this issue, we obtained simultaneous in vivo measurements of tumor burden and uptake of radiolabeled annexin V in the syngeneic orthotopic murine BCL 1 lymphoma model using in vivo bioluminescence imaging (BLI) and small animal single-photon emission computed tomography (SPECT). BCL 1 cells labeled for fluorescence and bioluminescence assays (BCL 1 − gfp/luc ) were injected into mice at a dose that leads to progressive disease within two to three weeks. Tumor response was followed by BLI and SPECT before and after treatment with a single dose of 10 mg/kg doxorubicin. Biodistribution analyses revealed a biphasic increase of annexin V uptake within the tumor-bearing tissues of mice. An early peak occurring before actual tumor cells loss was observed between 1 and 5 hr after treatment, and a second longer sustained rise from 9 to 24 hr after therapy, which heralds the onset of tumor cell loss as confirmed by BLI. Multimodality imaging revealed the temporal patterns of tumor cell loss and annexin V uptake revealing a better understanding of the timing of radiolabeled annexin V uptake for its development as a marker of therapeutic efficacy.https://doi.org/10.1162/15353500200403157 |
| spellingShingle | Stefanie J. Mandl Carina Mari Matthias Edinger Robert S. Negrin Jonathan F. Tait Christopher H. Contag Francis G. Blankenberg Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome Molecular Imaging |
| title | Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome |
| title_full | Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome |
| title_fullStr | Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome |
| title_full_unstemmed | Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome |
| title_short | Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome |
| title_sort | multi modality imaging identifies key times for annexin v imaging as an early predictor of therapeutic outcome |
| url | https://doi.org/10.1162/15353500200403157 |
| work_keys_str_mv | AT stefaniejmandl multimodalityimagingidentifieskeytimesforannexinvimagingasanearlypredictoroftherapeuticoutcome AT carinamari multimodalityimagingidentifieskeytimesforannexinvimagingasanearlypredictoroftherapeuticoutcome AT matthiasedinger multimodalityimagingidentifieskeytimesforannexinvimagingasanearlypredictoroftherapeuticoutcome AT robertsnegrin multimodalityimagingidentifieskeytimesforannexinvimagingasanearlypredictoroftherapeuticoutcome AT jonathanftait multimodalityimagingidentifieskeytimesforannexinvimagingasanearlypredictoroftherapeuticoutcome AT christopherhcontag multimodalityimagingidentifieskeytimesforannexinvimagingasanearlypredictoroftherapeuticoutcome AT francisgblankenberg multimodalityimagingidentifieskeytimesforannexinvimagingasanearlypredictoroftherapeuticoutcome |